BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30566242)

  • 1. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
    Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
    J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
    Senni N; Savall M; Cabrerizo Granados D; Alves-Guerra MC; Sartor C; Lagoutte I; Gougelet A; Terris B; Gilgenkrantz H; Perret C; Colnot S; Bossard P
    Gut; 2019 Feb; 68(2):322-334. PubMed ID: 29650531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1.
    Devereux TR; Stern MC; Flake GP; Yu MC; Zhang ZQ; London SJ; Taylor JA
    Mol Carcinog; 2001 Jun; 31(2):68-73. PubMed ID: 11429783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.
    Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C
    Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia.
    Suarez M I; Uribe D; Jaramillo CM; Osorio G; Perez JC; Lopez R; Hoyos S; Hainaut P; Pineau P; Navas MC
    Ann Hepatol; 2015; 14(1):64-74. PubMed ID: 25536643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
    Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
    J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
    Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
    Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.
    Rebouissou S; Franconi A; Calderaro J; Letouzé E; Imbeaud S; Pilati C; Nault JC; Couchy G; Laurent A; Balabaud C; Bioulac-Sage P; Zucman-Rossi J
    Hepatology; 2016 Dec; 64(6):2047-2061. PubMed ID: 27177928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
    Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
    Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway.
    Calderaro J; Nault JC; Bioulac-Sage P; Laurent A; Blanc JF; Decaens T; Zucman-Rossi J
    Virchows Arch; 2014 Jan; 464(1):53-60. PubMed ID: 24276407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling.
    Wang W; Li S; Liu P; Sideras K; van de Werken HJG; van der Heide M; Cao W; Lavrijsen M; Peppelenbosch MP; Bruno M; Pan Q; Smits R
    Mol Cancer Res; 2019 Feb; 17(2):521-531. PubMed ID: 30257989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
    Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
    Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
    Caruso S; Calderaro J; Letouzé E; Nault JC; Couchy G; Boulai A; Luciani A; Zafrani ES; Bioulac-Sage P; Seror O; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2017 Apr; 66(4):734-742. PubMed ID: 28012864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1+/- mice.
    Miyoshi H; Deguchi A; Nakau M; Kojima Y; Mori A; Oshima M; Aoki M; Taketo MM
    Cancer Sci; 2009 Nov; 100(11):2046-53. PubMed ID: 19671058
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Longerich T; Endris V; Neumann O; Rempel E; Kirchner M; Abadi Z; Uhrig S; Kriegsmann M; Weiss KH; Breuhahn K; Mehrabi A; Weber TF; Wilkens L; Straub BK; Rosenwald A; Schulze F; Brors B; Froehling S; Pellegrino R; Budczies J; Schirmacher P; Stenzinger A
    Gut; 2019 Jul; 68(7):1287-1296. PubMed ID: 30901310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.
    Qiao Y; Wang J; Karagoz E; Liang B; Song X; Shang R; Evert K; Xu M; Che L; Evert M; Calvisi DF; Tao J; Wang B; Monga SP; Chen X
    Hepatology; 2019 Dec; 70(6):2003-2017. PubMed ID: 30737831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.